Anti-Angiogenesis Treatment with Bevacizumab in Metastatic Breast Cancer
- Date: 16 Sep 2014
- Topic: Anticancer agents / Breast Cancer / Therapy / Biological therapy
Speaker: Jonas Bergh
J. Bergh comments on 3 studies on the use of bevacizumab in breast cancer: as adjuvant treatment in HER2 negative disease (E5103); as maintenance therapy in the metastatic setting (Arobase); as neoadjuvant treatment (Avataxher) in early HER2 positive breast cancer.
Discussion Points
- Can you provide a short recap of major results from the use of maintenance treatment in the Arobase (Gineco) study?
- What results is bevacizumab testing delivering in adjuvant and neoadjuvant trials?
- How important is the angiogenes pathway in breast cancer?
- What are the differences in the current bevacizumab licence for metastatic breast cancer between Europe and USA?
- Can you share your overall conclusion based on the studies with bevacizumab presented at ASCO 2014?